Full coverage· Health· Updated
Personalized mRNA Vaccine Shows Breakthrough Success in Preventing Skin Cancer Recurrence
A phase three trial shows a personalized mRNA vaccine combined with Keytruda effectively prevents skin cancer recurrence without new safety issues. The treatment, tailored to individual tumor mutations, may simplify production and reduce costs.
2 newsrooms · 1 language · since
Plus
What happened
- 01Phase three trial proves personalized mRNA vaccine prevents skin cancer recurrence effectively.
- 021,137 patients treated with vaccine plus Keytruda showed no new safety signals.
- 03Vaccine tailored to tumor mutations but does not require patient cells, easing production.
- 04Technology is also being tested for other cancers like lung cancer.
- 05Moderna and Merck stocks surged after results; pricing and regulatory talks upcoming.
- 06Analysts expect the treatment to generate about $3 billion in revenue by 2035.
Moderna and Merck stocks rose sharply after the results, with analysts forecasting substantial future revenues.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- Centre1
- RightNone
- Haredi1
- ArabNone